Testing a new drug combination for brain lymphoma that hasn't responded to prior treatment

Plain-English translation of NCT06737250 on ClinicalTrials.gov ↗ · Source last updated December 2024 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a three-drug combination—including a new medication called poseltinib—for people whose brain lymphoma has come back or stopped responding to earlier treatments. The study will enroll about 33 people and track how well this medication combination works and whether it is safe. Researchers hope this approach may help people when standard treatments are no longer effective.

Primary central nervous system lymphoma that returns or resists standard treatment is difficult to manage, and patients need new options. This trial exists to see whether this medication combination can offer hope for patients in that difficult situation.

Do you qualify?

You likely qualify if…

you are between 19 and 80 years old
you have been diagnosed with CD20-positive primary central nervous system lymphoma that has come back or stopped responding to treatment
your cancer has grown or resisted treatment after receiving no more than two prior systemic treatments and no more than one prior radiation therapy
you have measurable brain lesions visible on an MRI or CT scan
you are healthy enough to handle treatment, with an ECOG performance status score of 2 or lower (a measure of how well you can manage daily activities)
you agree to follow a pregnancy prevention plan if you are taking lenalidomide, and your doctor believes you will live at least 3 more months

You likely don't qualify if…

you were newly diagnosed with primary central nervous system lymphoma and have not yet received treatment
you have lymphoma only in the eyes without brain involvement
you have lymphoma that has spread outside the central nervous system to other organs in your body
your blood counts are too low, your kidney or liver function is severely impaired, or your calcium levels are too high
you have uncontrolled heart disease, a recent heart attack, or a blood clot or stroke within the last 6 months

What participation looks like

You will receive the medication combination in two phases. First, you'll have an induction phase lasting 6 cycles (about 18 weeks), where you take the medication by mouth twice daily, receive intravenous infusions of one of the other drugs, and take a third medication by mouth daily. After that, if the treatment is working, you'll move to a maintenance phase where you continue two of the medications until your cancer progresses. You'll have regular clinic visits and brain imaging to monitor how you're responding to treatment.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(10 sites)

South Korea

Kosin University Gospel Hospital, Busan

Chonnam National University Hwasun Hospital, Hwasun

Korea National Cancer Center, Ilsan

Seoul National University Bundang Hospital, Seongnam

Asan Medical Center, Seoul